Table 3 Univariate and multivariate analysis of factors associated with progression-free survival from start of first immunotherapy (n = 217)

Age ≥ 61 years

(n = 116)

0.77

(0.58–1.03)

0.076

0.78

(0.57–1.06)

0.111

Age < 61 years

(n = 101)

1.30

(0.97–1.73)

0.076

1.29

(0.94–1.76)

0.111

Female

(n = 122)

0.90

(0.67–1.20)

0.454

Male

(n = 95)

1.12

(0.84–1.49)

0.454

‘High’ BTLA

(n = 36)

0.59

(0.39–0.90)

0.015

0.77

(0.38–1.57)

0.475

‘High’ CTLA-4

(n = 41)

0.58

(0.39–0.87)

0.009

0.65

(0.32–1.31)

0.230

‘High’ LAG-3

(n = 51)

0.77

(0.54–1.09)

0.134

‘High’ NECTIN2

(n = 73)

1.19

(0.87–1.61)

0.273

‘High’ PD-1

(n = 44)

0.68

(0.47–0.98)

0.040

0.93

(0.54–1.59)

0.778

‘High’ PD-L1

(n = 36)

0.86

(0.58–1.27)

0.455

‘High’ PD-L2

(n = 51)

0.78

(0.55–1.11)

0.172

‘High’ PVR

(n = 72)

1.39

(1.03–1.89)

0.034

1.24

(0.89–1.73)

0.198

‘High’ TIGIT

(n = 39)

0.76

(0.52–1.13)

0.179

‘High’ TIM-3

(n = 44)

0.79

(0.55–1.13)

0.192

‘High’ TNFRSF14

(n = 39)

0.71

(0.48–1.05)

0.086

0.90

(0.58–1.41)

0.648

‘High’ VISTA

(n = 61)

0.89

(0.64–1.23)

0.476

Lung Cancer

(n = 14)

0.94

(0.52–1.68)

0.827

Colorectal Cancer

(n = 54)

1.20

(0.86–1.67)

0.295

Breast Cancer

(n = 19)

1.04

(0.62–1.73)

0.890

Ovarian Cancer

(n = 18)

1.08

(0.65–1.81)

0.759

Pancreatic Cancer

(n = 16)

1.40

(0.82–2.38)

0.213

Uterine Cancer

(n = 12)

0.76

(0.40–1.45)

0.409

Neuroendocrine Tumor

(n = 24)

0.98

(0.36–2.65)

0.972

Sarcoma

(n = 15)

0.61

(0.30–1.24)

0.169

TMB < 10 mut/mB

(n = 169)^a

1.59

(0.96–2.63)

0.083

1.45

(0.87–2.43)

0.153

TMB ≥ 10 mut/mB

(n = 22)^a

0.63

(0.38–1.04)

0.083

0.69

(0.41–1.15)

0.153